The discovery that blocking CTLA-4 can enhance antitumor immunity has led to the development of CTLA-4 inhibitors, such as ipilimumab, the first immune checkpoint inhibitor authorized by the United States Food and Drug Administration (FDA) for melanoma treatment. Here, CTLA4 is linked to melanoma.